A February 9, 2026, federal complaint filed by Novo Nordisk was followed by a March 9 voluntary dismissal and an agreement with Hims & Hers to offer FDA-approved GLP-1 medications through its platform. The development relates to telehealth-based access to GLP-1 medications and is relevant to compliance requirements for Med Spa operators offering weight-loss treatments.
Lawsuit Dismissal and GLP-1 Agreement Mark Shift in Telehealth Access
Novo Nordisk filed a patent infringement complaint against Hims & Hers Health, Inc. and Hims, Inc. on February 9, 2026, in the U.S. District Court for the District of Delaware and dismissed the case on March 9, according to a Notice of Voluntary Dismissal. On March 9, Hims & Hers announced an agreement with Novo Nordisk to offer Wegovy and Ozempic through its platform. For Med Spa operators, the development involves access to FDA-approved GLP-1 medications through telehealth platforms and reduced reliance on compounded alternatives in weight-loss programs.
Novo Nordisk Patent Complaint and Dismissal Precede GLP-1 Platform Agreement
Novo Nordisk filed a patent infringement complaint on February 9, 2026, in the U.S. District Court for the District of Delaware involving U.S. Patent No. 8,129,343 B2, related to semaglutide-based medications. The case was dismissed on March 9 following a Notice of Voluntary Dismissal.
In a March 9 statement, Hims & Hers announced it had entered into an agreement with Novo Nordisk to offer FDA-approved GLP-1 medications, including Wegovy and Ozempic, through its platform.
The company said the agreement is part of a broader update to its weight-loss strategy, including providing access to a broader range of FDA-approved GLP-1 treatments and ending advertising of compounded GLP-1 offerings. Hims & Hers also stated it will transition eligible patients to FDA-approved medications when clinically appropriate.
The announcement describes a model in which telehealth platforms connect patients with licensed providers for prescribing and ongoing management. In Med Spa settings, this structure includes remote providers conducting required medical evaluations, including determining whether a good-faith exam is required for GLP-1 treatments prior to prescribing.
GLP-1 Prescribing and Telehealth Oversight in Med Spa Settings
The March 9 agreement between Novo Nordisk and Hims & Hers reflects distinctions between FDA-approved GLP-1 medications and compounded alternatives in weight-loss treatment programs. FDA-approved drugs such as Wegovy and Ozempic are distributed through manufacturer-controlled channels, while compounded versions are prepared by pharmacies and are subject to different regulatory and marketing requirements.
On March 3, 2026, the FDA issued warning letters to telehealth companies for marketing compounded GLP-1 drugs with claims the agency described as false or misleading. The letters addressed how these products were promoted to patients, including representations related to safety, effectiveness, and equivalence to FDA-approved medications.
In Med Spa settings, telehealth-based prescribing models are governed by state laws related to medical evaluation, supervision, and documentation. These frameworks define how patients are assessed, how prescribing authority is exercised, and how clinical records are maintained. Telehealth models also involve handling patient health information across digital platforms. These workflows involve considerations related to data privacy, informed consent, and secure communication.
Practical Implications for Med Spa Operators
- Recognize that FDA-approved GLP-1 medications are distributed through manufacturer-controlled channels, while compounded alternatives follow different regulatory pathways.
- Confirm that telehealth prescribing models include evaluation and oversight by a licensed provider prior to treatment initiation.
- Distinguish clinical and marketing representations of FDA-approved medications from compounded alternatives.
- Maintain documentation of patient assessments, prescribing decisions, and ongoing treatment management.
- Ensure telehealth workflows align with requirements for patient privacy, informed consent, and secure communication.
Regulatory and Market Developments to Monitor
The March 9 agreement between Novo Nordisk and Hims & Hers reflects developments in how FDA-approved GLP-1 medications are offered through telehealth platforms. On March 3, 2026, the FDA issued warning letters addressing how compounded GLP-1 products are promoted and represented under existing regulatory requirements. Both developments relate to GLP-1 prescribing, distribution, and marketing across telehealth and Med Spa settings.
About Spakinect
Spakinect provides compliance infrastructure and telehealth-supported supervision solutions for medical aesthetic practices. For additional information, see our website.
Image Attribution: “DelCourtChancery2022” by Nolabob, via Wikimedia Commons, licensed under CC BY-SA 4.0.
